Generate Biomedicines, Inc.
Generate Biomedicines, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD on May 15, 2027. There are 4 upcoming events on record.
Cash runway is approximately 17.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| May 15, 2027 | A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD | Trial Milestone | Phase 1 |
| June 15, 2027 | Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer | Trial Milestone | Phase 1 |
| December 15, 2028 | A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) | Trial Milestone | Phase 3 |
| January 15, 2029 | A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) | Trial Milestone | Phase 3 |
Track GENB alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open GENB in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 30, 2026 | Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants | Trial Milestone | Phase 1 |
| August 26, 2026 | 8-K filed: Reg FD disclosure | Filing | — |
| August 6, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 7, 2026 | Quarterly results filed (8-K) | Earnings | — |
| November 22, 2024 | Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants | Trial Milestone | Phase 1 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.